Unlocking the Truth About Zyprexa and Weight Loss: What You Need to Know!

Olanzapine, commonly known as Zyprexa, is an atypical antipsychotic medication prescribed to treat schizophrenia and bipolar disorder. While effective in managing symptoms like hallucinations and mood swings, it's associated with significant side effects, particularly weight gain. This article delves into the complexities of olanzapine-related weight gain, exploring its causes, health implications, and strategies for management, incorporating insights from registered dietitians and scientific studies.

How Olanzapine Works

Olanzapine functions by balancing brain chemicals, primarily dopamine and serotonin, which helps to alleviate symptoms of schizophrenia, such as hallucinations and delusions. In individuals with bipolar disorder, it stabilizes mood swings, addressing both manic and depressive phases.

The Connection Between Olanzapine and Weight Gain

Weight gain is a well-recognized side effect of antipsychotics like olanzapine, often referred to as antipsychotic-induced weight gain (AIWG). Olanzapine and clozapine, in particular, can trigger intense hunger cravings, affect metabolism, lead to insulin resistance, and accelerate fat storage.

Mechanisms Behind Weight Gain

Increased Hunger and Cravings: Olanzapine affects hunger-regulating receptors and other chemicals in the brain, leading to intense food cravings and a constant urge to binge eat. Many people report intense food cravings on olanzapine and the constant urge to binge eat.
Slowed Metabolism: The medication can tweak your metabolism, dialing down your calorie-burning efficiency, which leads to weight gain. So, you’re eating more but burning less energy.
Encouraged Fat Storage: Olanzapine alters how the body handles fats and sugars, promoting increased fat storage.
Insulin Resistance: Long-term use of olanzapine has been linked to insulin resistance, contributing to weight gain and obesity. A study shows that long-term use of olanzapine is linked to insulin resistance, which leads to weight gain and obesity.
Sedation and Reduced Activity: Olanzapine can cause drowsiness by blocking histamine receptors in the brain, leading to reduced physical activity and subsequent weight gain. Olanzapine can indirectly cause weight gain through sedation. This happens because it blocks histamine receptors in the brain, which are important for keeping you awake.

Health Effects of Weight Gain from Zyprexa

Weight gain from olanzapine can have significant repercussions on both mental and physical health.

Mental Health Effects

Weight gain can negatively impact mental well-being, potentially leading to decreased self-esteem, body image issues, and an increased risk of depression. Since olanzapine and clozapine ramp up the urge to eat, they may be a worrisome trigger for people with body dysmorphia or eating disorders like bulimia, binge eating disorder, or orthorexia.

Read also: Weight Loss Guide Andalusia, AL

Physical Health Effects

Weight gain can increase the risk of obesity and diabetes because studies show that antipsychotics also block dopamine receptors in the pancreas, making you gain weight faster and increasing your risk of diabetes. It can also raise cholesterol levels and the risk of heart disease, potentially leading to metabolic syndrome. People with obesity and metabolic syndrome may also be more likely to relapse or be re-hospitalized due to symptoms of severe mental illness.

Strategies for Weight Management While on Olanzapine

It’s crucial to consult with a healthcare provider before making any changes to your medication regimen.

Medical Interventions

Metformin: Doctors may prescribe metformin to counteract weight gain from antipsychotics like olanzapine.
Lybalvi: This medication combines olanzapine with samidorphan to reduce weight gain.
Alternative Antipsychotics: Some antipsychotics, like aripiprazole (Abilify), cause less weight gain, but only your healthcare provider can help you figure out what meds work best for you.
Emerging Treatments: There's also an ongoing discussion in the medical community about whether Ozempic, Wegovy, or Mounjaro could help with weight loss in olanzapine users.

Managing Food Cravings

Managing food cravings due to antipsychotic-induced weight gain (AIWG) requires a balanced approach. It is essential to recognize that weight gain is a common side effect of these medications. Focus on making nutritious foods more accessible while keeping 'fun foods' as occasional treats.

Practical Tips for Managing Cravings

Identify Patterns in Hunger Cravings: Observe when cravings occur, such as after eating, late at night, or between meals, to develop effective coping strategies. Pay attention to times of transition, like your commute or after dinner.
Delayed Gratification: Slowly extend the time between feeling a craving and indulging in it to weaken its hold. Try to drink a glass of water before eating that bag of chips or drinking that soda. Eat some protein and healthy fats before you indulge your cravings to help control insulin spikes. Keep low-calorie, easy-to-grab, fiber-rich snacks on hand. Practice urge surfing by acknowledging your cravings and riding the wave.
Lower Dependence on Added Sugars: Reduce intake of added sugars found in processed foods and drinks, which are linked to obesity and other health issues. Before your usual sugar cravings start, try eating natural sugars.
Balance Your Plate: Focus on whole vegetables, whole fruits, whole grains, lean meats, and healthy fats. You could add a green salad before lunch and dinner. Consider starting your day with a savory breakfast containing proteins and fats.
Seek Personalized Support: Working with a psychiatrist and a Registered Dietitian for support could help you achieve your goals.

Additional Considerations

Regular Monitoring: Your doctor should regularly check your progress to ensure the medication is working properly and to monitor for unwanted effects.
Awareness of Potential Side Effects: Be vigilant for any abnormal behaviors, suicidal thoughts, or symptoms of serious conditions like drug reaction with eosinophilia and systemic symptoms (DRESS) or neuroleptic malignant syndrome (NMS).
Caution with Other Substances: Avoid alcohol and other central nervous system depressants while taking olanzapine.

Olanzapine-Induced Weight Loss: An Exception

While weight gain is a common side effect of olanzapine, there are rare cases where weight loss occurs. Atypical antipsychotics induce weight gain by H1 blockade and 5-HT2C antagonism actions on proopiomelanocortin neurons. For some individuals, however, clozapine use has been associated with significant weight loss (13.5%-50% of body weight). Similarly, this could be the case with olanzapine in some patients. In such instances, it's important to rule out underlying physical disorders, negative symptoms, or other contributing factors.

Case Study: Olanzapine and Weight Loss in Early-Onset Schizophrenia

A 15-year-old boy with early-onset schizophrenia, maintained on olanzapine, experienced diminished appetite and weight loss (7 kg [15 lb] over 2 weeks) as well as terminal insomnia. Negative symptom domain (deficit state): look for other A’s (affective flattening, alogia, avolia, abulia, anhedonia, asociality, and attentional impairment). Physical presentation: assess for diabetes, thyrotoxicosis, parasitic infestation, and poor dental hygiene. Inpatient psychosocial treatment, including rehabilitation, social skills training, and cognitive remediation, was provided by our occupational therapy staff. Dietary advice was summoned. Cosmetic psychopharma. The case was discussed in our hospital grand rounds, and a trial of shifting the patient from olanzapine (Zydis) to a regular formulation was suggested based on a 1-year open-label prospective study11 wherein patients incurred an average weight loss of 2.7 ± 0.7 kg (P = .001) after switching from olanzapine standard oral tablets to olanzapine orally disintegrating tablets at 12 months. A shift to regular formulation resulted in gaining an extra half kilo (1 lb) in 2 weeks. Add-on mirtazapine, albeit off label, was then suggested for our patient, and his parents’ consent was obtained beforehand. It was titrated up to 60 mg/d over 4 weeks. Better interpersonal socialization was noted as was engagement with occupational therapy. The patient gained 4 kg (9 lb).

Metformin and Olanzapine-Induced Weight Gain: A Systematic Review

A meta-analysis was performed to see the effect size of the treatment on body weight, waist circumference and body-mass index (BMI). Weighted mean difference (WMD) for body weight was 5.02 (95% CI 3.93, 6.10) kg lower with metformin as compared with placebo at 12 weeks. For waist circumference, the test for heterogeneity was significant (P= 0.00002, I2= 85.1%). Therefore, a random effects model was used to calculate WMD, which was 1.42 (95% CI 0.29, 3.13) cm lower with metformin as compared with placebo at 12 weeks. For BMI, WMD was 1.82 (95% CI 1.44, 2.19) kg m−2 lower with metformin as compared with placebo at 12 weeks. Existing data suggest that short term modest weight loss is possible with metformin in patients with olanzapine-induced weight gain. In our meta-analysis, weight reduction was 5.02% with metformin, which was higher that for the approved drugs for weight reduction such as orlistat and sibutramine, which reduced body weight by only 2.9% and 4.3%, respectively [28]. The adverse events reported with metformin were similar to placebo groups. These results encourage additional studies in more homogenous populations on the potential use of metformin in assisting olanzapine-treated patients in the long-term control of body weight and BMI. Baseline screening and a monitoring plan must be initiated on commencement of antipsychotic treatment [29].

Olanzapine and Serotonin 2C Receptor (HTR2C)

Atypical antipsychotics such as olanzapine often induce excessive weight gain and type 2 diabetes. However, the mechanisms underlying these drug-induced metabolic perturbations remain poorly understood. We found that olanzapine treatment acutely increased food intake, impaired glucose tolerance, and altered physical activity and energy expenditure in mice. Furthermore, olanzapine-induced hyperphagia and weight gain were blunted in mice lacking the serotonin 2C receptor (HTR2C). Finally, we showed that treatment with the HTR2C-specific agonist lorcaserin suppressed olanzapine-induced hyperphagia and weight gain. Lorcaserin treatment also improved glucose tolerance in olanzapine-fed mice. Our data suggest that olanzapine-induced hyperphagia is the primary cause of weight gain in mice and that olanzapine’s effect on food intake is mediated by Htr2c. Furthermore, we demonstrate that olanzapine-induced hyperphagia is reduced by a HTR2C-specific agonist treatment in olanzapine-fed mice, accompanied by an improvement in glucose homeostasis.

Read also: Inspiring Health Transformation

tags: #zyprexa #weight #loss #information